Innovent Biologics, Inc. (Innovent), orinasa biopharmaceutical kilasy manerantany izay mamolavola, manamboatra ary mivarotra fanafody avo lenta ho fitsaboana homamiadana, metabolika, autoimmune ary aretina lehibe hafa, ary NeoCura Bio-Medical Technology Co., Ltd. ( NeoCura), orinasa bioteknolojia momba ny fitsaboana amin'ny fanafody RNA mahomby amin'ny AI izay manolo-tena amin'ny fananganana sehatra zava-mahadomelina vaovao RNA manerantany, dia nanambara androany fa nanao fifanarahana fiaraha-miasa stratejika izy ireo mba hanatanteraka fandalinana klinika any Shina momba ny fitsaboana mitambatra amin'ny sintilimab. avy amin'ny Innovent sy vaksiny neoantigen manokana NEO_PLIN2101 avy amin'ny NeoCura.

eTurboNews lahatsoratra dia natao ho an'ny mpanjifa ihany. Ny famandrihana dia FREE.
Misoratra anarana eto Tsindrio eto raha hisoratra anarana MAIMAIMPOANA

INONA NO HALAINA AMIN'Ity ARTICLE ITY:

(NeoCura), a leading AI-enabled RNA precision medicine biotech company committed to building a global top RNA innovative drug platform, today jointly announced that they have entered into a strategic collaboration agreement to carry out a clinical study in China on the combination therapy of sintilimab from Innovent and individualized neoantigen vaccine NEO_PLIN2101 from NeoCura.
(Innovent), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and NeoCura Bio-Medical Technology Co.
eTurboNews lahatsoratra dia natao ho an'ny mpanjifa ihany.